July 16, 2025Expert Opinion on Therapeutic Patents

Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)

View Full Paper

Ask AI

Bookmark

Fourth-generation EGFR tyrosine kinase inhibitors address resistance mechanisms like C797S mutation in NSCLC.
Osimertinib, a third-generation inhibitor, is effective against T790M mutations but limited by acquired C797S resistance.
Recent patents showcase compounds such as aminopyrimidine and quinazoline designed for selective EGFR targeting.
Clinical trials of inhibitors like BDTX-1535 reveal significant promise in redefining NSCLC therapy through innovative strategies.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This review discusses how fourth-generation EGFR tyrosine kinase inhibitors target mutations like C797S, suggesting new treatment avenues for non-small cell lung cancer.

Cite This Study

Nagpure et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8ccc50 https://doi.org/10.1080/13543776.2025.2536006

View Full Paper

Ask AI

Bookmark

Implication

This review discusses how fourth-generation EGFR tyrosine kinase inhibitors target mutations like C797S, suggesting new treatment avenues for non-small cell lung cancer.

Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)

Key Points

Discussion

Implication

Cite This Study

Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider